Halia Therapeutics Appoints Paul Jones as Chief Strategy Officer

Halia Therapeutics has appointed Paul Jones as its new Chief Strategy Officer and General Manager for International Markets. This role, established to enhance the company’s leadership in genomics, highlights Halia’s ongoing commitment to developing resilience-based therapies. The announcement was made on October 6, 2025, from the company’s headquarters in Lehi, Utah.

In his new capacity, Jones will focus on accelerating the growth of GENMOR-AI, Halia’s proprietary platform that utilizes artificial intelligence to identify genetic modifiers of disease. His appointment is expected to significantly bolster Halia’s collaboration with the Department of Health – Abu Dhabi, which is utilizing the Emirati Genome dataset to uncover genetic resilience factors that may protect individuals from various diseases.

“We are thrilled to welcome Paul to Halia. His proven track record in large-scale genomics initiatives—from the UK’s 100,000 Genomes Project to the Emirati Genome Programme—makes him an exceptional addition to our leadership team,” said David Bearss, Ph.D., CEO of Halia Therapeutics. “His expertise in translating genomic insights into healthcare solutions aligns with our mission to develop transformative medicines based on resilience biology.”

Jones brings over 30 years of experience in life sciences, particularly in genomics and digital health transformation. His previous roles include serving as CEO of the Omics Centre of Excellence at M42, a global health company based in Abu Dhabi. There, he played a pivotal role in the Emirati Genome Program, one of the most ambitious national genomics initiatives globally. His extensive background also includes positions at Illumina, Genomics England, Cisco, Novartis, IMS Health, and PwC.

Jones’s appointment is expected to enhance Halia’s APOE4 program, which focuses on Alzheimer’s disease. This program studies individuals who carry the highest-risk genetic variant yet do not develop the condition. Through the application of GENMOR-AI on population-scale genomic datasets, Halia aims to identify resilience mechanisms that could inform new therapeutic developments for various conditions, including neurodegeneration, metabolic disorders, cardiovascular diseases, and cancer.

“I’m excited to join Halia at this pivotal moment,” Jones stated. “The company’s unique focus on genetic resilience—rather than just disease risk—represents the next frontier in precision medicine. By combining cutting-edge AI with strategic global partnerships, Halia is positioned to revolutionize drug discovery and patient outcomes.”

Halia Therapeutics is committed to addressing the root causes of inflammation. The company leverages genetic insights and AI-enabled discovery to develop a robust pipeline of novel therapeutics targeting inflammatory pathways in diseases ranging from metabolic disorders to hematologic malignancies. Its mission is to create data-driven therapies that enhance the quality of life while extending longevity.

For further information about Halia Therapeutics, visit their website at [www.haliatx.com](http://www.haliatx.com) or follow them on LinkedIn and Twitter @HaliaTx.

Contact details for inquiries:
Taylor Avei
Director of Business Development
Halia Therapeutics
Email: [email protected]
Phone: +1 (385) 355-4315

Leigh Salvo
New Street Investor Relations
Email: [email protected]